Excellent
Excellent
Patient Risk:
Low
Summary
All claims about diazepam pharmacokinetics (half-life, active metabolites, detectability, and prolonged effect with repeated use) are supported by the label's pharmacokinetics section (Section 12.3). No contradictions or unsupported statements detected.
Category Scores
Accurate Statements
Diazepam elimination half-life is typically about 20 to 50 hours.
Section 12.3 Pharmacokinetics
Diazepam is slowly cleared.
Section 12.3 Pharmacokinetics
Diazepam is metabolized into active metabolites that persist.
Section 12.3 Pharmacokinetics
Diazepam is metabolized to active metabolites, especially desmethyldiazepam (nordiazepam).
Section 12.3 Pharmacokinetics
Desmethyldiazepam (nordiazepam) has its own long half-life.
Section 12.3 Pharmacokinetics
Desmethyldiazepam's long half-life contributes to the prolonged overall effect of diazepam.
Section 12.3 Pharmacokinetics
Desmethyldiazepam's long half-life contributes to the wide half-life range reported for diazepam.
Section 12.3 Pharmacokinetics
Diazepam can remain detectable for several days after dosing in many people.
Section 12.3 Pharmacokinetics
Diazepam can remain pharmacologically active for several days after dosing in many people.
Section 12.3 Pharmacokinetics
This is especially true with repeated use.
Section 12.3 Pharmacokinetics
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims pertain to pharmacokinetics and do not introduce new safety risks beyond labeling.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Excellent
Primary Issue
Suggested Improvement